With a history of innovation, the company is at the origin of a new generation of allergy immunotherapy treatments. Upon its creation, Stallergenes Greer brought an essential contribution to allergy therapies at a time when symptomatic treatments were the gold standard. These efforts have considerably strengthened the level of evidence supporting allergy immunotherapy.

Learn more about our history

Our ambition

Becoming the world's leading allergen immunotherapy company, by:

Realising the potential of precision medicine combined with personalised healthcare to improve the quality of life of people with allergies

  • With precision medicine, we identify the mechanisms of allergic response to develop diagnostic tools and AIT treatments
  • Our ambition is to deliver unparalleled personalised patient care through our extensive product portfolio, including all administration routes
  • We continue to develop treatment solutions which can be adjusted to meet patient-specific profiles and needs

Changing the course of allergic disease through the largest portfolio of best-in class allergy AIT treatments

  • We focus on delivering state-of-the-art quality products
  • We deepen our knowledge of AIT and meet modern methodological standards for proving efficacy and safety

Nurturing scientific innovation and collaborating for long-term growth, creating value for our stakeholders

  • We empower clinicians to make therapeutic decisions based on patients’ needs due to our broad AIT product portfolio
  • We strive to offer patients unparalleled support
  • We contribute to our society, where climate change and increasing pollution will result in half of people having allergies by 2050

Being a trusted partner in allergy management and making a lasting and positive contribution to society

  • We unlock the potential of every colleague with lifelong learning and development
  • We build on our pioneering heritage to embed innovative thinking into our ways of working, benefiting our people, patients and physicians
  • We improve patient experience by collaborating with partners in technological innovation, molecular research and developments in allergy biomarkers and drug delivery methodologies

Our strategy >

At Stallergenes Greer, we operate to sustain growth and create value for society as a whole.

The company’s strategy is based on three pillars: precision medicine for better patient care, investing in our people, a high-performance agile organisation.

Learn more about our strategy